Key result
CYP2C19 loss-of-function polymorphisms and concomitant aspirin use were significantly associated with clopidogrel response status in patients with ACS or ischemic stroke.
Why the study?
Do CYP2C19 loss-of-function polymorphisms and clinical variables impact platelet response to clopidogrel in patients with acute coronary syndromes or ischemic stroke?
Population
189 clopidogrel-treated patients with acute coronary syndromes and noncardiogenic ischemic stroke from an…
Design
Cohort
Authors
Loading...
Does not yet support routine CYP2C19 testing in ACS or stroke; extends associations to East European patients but requires prospective confirmation.
Observational (n=189)
Do CYP2C19 loss-of-function polymorphisms and clinical variables impact platelet response to clopidogrel in patients with acute coronary syndromes or ischemic stroke?
In an East European population with ACS or ischemic stroke, clopidogrel resistance was present in 19% of patients and was significantly influenced by CYP2C19 polymorphisms and concomitant aspirin use.
Mărginean et al. (2016) conducted an observational in Acute coronary syndromes and noncardiogenic ischemic stroke (n=189). CYP2C19 loss-of-function polymorphisms vs. CYP2C19 wild-type homozygotes was evaluated on Clopidogrel response status (responder vs nonresponder). CYP2C19 loss-of-function polymorphisms and concomitant aspirin use were significantly associated with clopidogrel response status in patients with ACS or ischemic stroke.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: